Dihydroergocryptine
Generic medicine reference
Not yet clinically reviewed
This entry was migrated from the earlier Pharmapedia app bundle and has not been reviewed by a named clinician on this site. It is provided for educational reference only — verify dosage and safety information against current, authoritative sources and a qualified healthcare professional before any clinical use.
Overview
Dihydroergocryptine is a dopamine agonist of the ergoline group that is used as an antiparkinson agent in the treatment of Parkinson's disease. Dihydroergocryptine used in the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease. It is taken by mouth.
Indications
Dihydroergocryptine is primarily indicated in conditions like Cerebro-vascular insufficiency, Chronic venous insufficiency, Ischaemic heart disease, Migraine, Parkinsonism, and can also be given in adjunctive therapy as an alternative drug of choice in Behavioral disorders, Lactation inhibition, Peripheral vascular disease, Psychiatric disease, Raynaud's disease.
Contraindications
Dihydroergocryptine is contraindicated in conditions like Psychosis, Hypersensitivity to the drug.
Side Effects
Hydergine ® (ergoloid mesylates) preparations have not been found to produce serious side effects. Transient nausea and gastric disturbances have been reported. Hydergine ® (ergoloid mesylates) preparations do not possess the vasoconstrictor properties of the natural ergot alkaloids.
Warnings
There is evidence that exposure to Dihydroergotamine (a migraine drug) during pregnancy to give a teratogenic effect on the fetus. A teratogen is a substance that can cause birth defects. The likelihood and severity of the defects may be influenced by the level of exposure and the stage of pregnancy at which exposure occurred.
High Risk Groups
Drug should not be given to Pregnant Mothers. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Adult Dosage
2 to 4 mg (3 (3)) 12 hourly PO —
Scraped Dose — 1 mg three times daily.
Alleviation of symptoms is usually gradual and results may not be observed for 3-4 weeks.
Child Dosage
No child dosage information is recorded for this medicine yet.
Neonatal Dosage
No neonatal dosage information is recorded for this medicine yet.
Drug Interactions
No data regarding the interactions of Dihydroergocryptine was found.
Storage
No storage information is recorded for this medicine yet.
Available Brands in Pakistan
No brands are recorded for this generic.